Vaccines against epidemic and pandemic influenza

Expert Opinion on Drug Delivery

Volumn 5, Issue 10, 2008, Pages 1139-1157

  Hoelscher, Mary ^a   Gangappa, Shivaprakash ^a   Zhong, Weimin ^a   Jayashankar, Lakshmi ^a   Sambhara, Suryaprakash ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

H5N1; H9N2; Influenza; Pandemic; Seasonal; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM HYDROXIDE; ARSENIC TRIOXIDE; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PLACEBO;

BELL PALSY; CELL LINE; CELLULAR IMMUNITY; CLINICAL TRIAL; CULTURE TECHNIQUE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PROTEIN TARGETING; REVIEW; SEASONAL VARIATION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRUS CULTURE; VIRUS LIKE AGENT; VIRUS STRAIN; VIRUS VIRULENCE; WHEEZING;

ANIMALS; BIRDS; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS IMMUNIZATION; PUBLIC HEALTH; RISK FACTORS; TECHNOLOGY, PHARMACEUTICAL;

EID: 55049106378     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.10.1139     Document Type: Review

References (165)

1. State-specific influenza vaccination coverage among adults aged > or = 18 years - United States, 2003-04 and 2005-06 influenza seasons. MMWR Morb Mortal Wkly Rep 2007;56(37):953-9
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289(2):179-86
3. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008;121(4):258-64
4. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 1987;136(3):550-5
5. Mak TK, Mangtani P, Leese J, et al. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008;8(1):44-52
6. Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148(11):1094-102
7. Schrag SJ, Fiore AE, Gonik B, et al. Vaccination and perinatal infection prevention practices among obstetrician-gynecologists. Obstet Gynecol 2003;101(4):704-10
8. Influenza vaccination in pregnancy: practices among obstetrician-gynecologists - United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep 2005;54:1050-2
9. Lu P, Bridges CB, Euler GL, Singleton JA. Influenza vaccination of recommended adult populations, US, 1989-2005. Vaccine 2008;26(14):1786-93
10. DHHS. Healthy People 2010: Understanding and improving health and objectives for improving health. 2000 [cited 2008 August 20]. Available from: http://www.healthypeople.gov/Document/Word/uih/uih.doc
11. NCHS. Early release of selected estimates based on data from the January-September 2006 National Health Interview Survey (NHIS). 2007 March 28 [cited 2008 August 20]. Available from: http://www.cdc.gov/nchs/ about/major/nhis/released200803.htm#5
12. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005;352(4):333-40
13. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006;355(21):2186-94
14. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis 2007;13(9):1348-53
15. de Jong JC, Claas EC, Osterhaus AD, et al. A pandemic warning? Nature 1997;389(6651):554
16. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279(5349):393-6
17. WHO. Cumullative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO. 2008. [cited 2008 August 10]. Available from: http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2008_02_28/en/index.html
18. OIE. Avian influenza country count. 2008 [cited 2008 August 10]. Available from: http://www.oie.int/downld/AVIAN%20INFLUENZA/A_AI-Asia.htm
19. WHO. Phylogenetic Tree from the Evolution Working Group Poster. 2007 [cited 2008 August 10]. Available from: http://www.who.int/entity/csr/ disease/influenza/tree_large.pdf
20. Alexander DJ. A review of avian influenza in different bird species. Vet Microbiol 2000;74(1-2):3-13
21. Henzler DJ, Kradel DC, Davison S, et al. Epidemiology, production losses, and control measures associated with an outbreak of avian influenza subtype H7N2 in Pennsylvania (1996-98). Avian Dis 2003;47(3 Suppl):1022-36
22. Guo Y, Li J, Cheng X. Discovery of men infected by avian influenza A (H9N2) virus. Zhonghua Shi YanHe LinChuangBing Du Xue Za Zhi 1999;13(2):105-8
23. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999;354(9182):916-7
24. First Nasal Mist Flu Vaccine Approved. 2003 June 17 [cited 2008 August 20]. Available from: http://www.fda.gov/bbs/topics/NEWS/2OO3/ NEWO0913.html
25. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284(13):1655-63
26. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997;176(Suppl 1):20-3
27. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158(16):1769-76
28. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985;253(8):1136-9
29. Govaert TM, Sprenger MJ, Dinant GJ, et al. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994;12(13):1185-9
30. Halasa NB, Gerber MA, Chen Q, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 2008;197(10):1448-54
31. Prevention CfDCa. Preliminary assessment of the effectiveness of the 2003-2004 inactivated influenza vaccine - Colorado, December 2003. MMWR Morb Mortal: Wkly Rep 2004;53(1):8-11
32. Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184(6):665-70
33. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations. Pediatrics 2006;117(4):e610-8
34. Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995;171(6):1595-9
35. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49(3):177-84
36. Baldo V, Baldovin T, Floreani A, et al. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007;25 (20):3955-61
37. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003;21(27-30):4234-7
38. Chuang TH, Lee J, Kline L, et al. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 2002;71(3):538-44
39. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408(6813):740-5
40. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998;16(11-12):1216-24
41. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper- l-promoting adjuvants. Nat Med 1997;3(8):849-54
42. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22(23-24):3136-43
43. Gluck R, Mischler R, Durrer P, et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 2000;181(3):1129-32
44. Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 2002;20(Suppl 5):10-6
45. Zurbriggen R. Immunostimulating reconstituted infiuenza virosomes. Vaccine 2003;21(9-10):921-4
46. Bungener L, Serre K, Bijl L, et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002;20(17-18):2287-95
47. Sheridan C. Production technologies change flu vaccine landscape. Nat Biotechnol 2007;25(7):701
48. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007;297(14):1577-82
49. Epidemic Influenza Vaccine. 2006 [cited 2008 August 21]. Available from: http://www.crucell.com/ R_and_D-Clinical_Development-Epidemic_Influenza_Vaccine
50. Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002;20(7-8):1240-7
51. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990;64(4):1808-11
52. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983;303(5919):706-9
53. Bruhl P, Kerschbaum A, Kistner O, et al. Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. Vaccine 2000;19(9-10):1149-58
54. Baxter announces preliminary Phase I/II data for seasonal influenza vaccine candidate. Available from: http://www.baxter.com/about_baxter/ news_room/news_releases/2007/07-23-07-vaccine seasonal_flu.html
55. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136(2):168-75
56. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982;146(6):780-90
57. Klimov AI, Cox NJ, Yotov WV, et al. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus. Virology 1992;186(2):795-7
58. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999;18(9-10):899-906
59. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006;355(24):2513-22
60. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356(7):685-96
61. Cox NJ, Bridges CB. Inactivated and live attenuated influenza vaccines in young children - how do they compare? N Engl J Med 2007;356(7):729-31
62. Belshe R, et al. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008 Jul 9. [Epub ahead of print].
63. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001;20 (8):733-40
64. Mansell R Novel FluVacc vaccine enters phase I trial. 2007 [cited 2008 Match 15]. Available from: http://www.in-pharmatechnologist.com/news/ ng.asp? id=76666-avir-green-hills-biotechnology-medical-university-of- vienna-influenza-vaccine-fluvacc
65. Pichlmair A, Schulz O, Tan CP, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006;314(5801):997-1001
66. Guo Z, Chen LM, Zeng H, et al. NS1 Protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol 2007;36(3):263-69
67. Mibayashi M, Martinez-Sobrido L, Loo YM, et al. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 2007;81 (2):514-24
68. Opitz B, Rejaibi A, Dauber B, et al. IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell Microbiol 2006
69. Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998;178(1):53-60
70. Wood JM, Major D, Daly J, et al. Vaccines against H5N1 influenza. Vaccine 1999;18(7-8):579-80
71. Lu X, Tumpey TM, Morken T, et al. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999;73(7):5903-11
72. Takada A, Kuboki N, Okazaki K, et al. Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 1999;73(10):8303-7
73. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357(9272):1937-43
74. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21 (15):1687-93
75. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic Avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191(8):1210-5
76. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994;68 (5):3120-8
77. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001;14(1):129-49
78. Subbarao K, Chen H, Swayne D, et al. Evaluation of a genically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305(1):192-200
79. Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999;179(5):1132-8
80. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354(13):1343-51
81. Center for Infectious Disease R, Policy. FDA panel supports H5N1 vaccine approval. 2007 [cited 2008 August 20]. Available from: http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/ feb2707vaccine.html
82. Zangwill KM, Treanor JJ, Campbell JD, et al. Evaluation of the safety and immunogenicity of a booster (Third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008;197(4):580-3
83. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367(9523):1657-64
84. Keitel W, Campbell J, Treanor J, et al. A phase I-II, randomized, controlled, dose ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminium hydroxide to healthy adults. Options for the Control of Influenza VI; 2007 June 17-23; Toronto, Ontario, Canada
85. Brady R, Treanor J, Atmar R, et al. A phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminium hydroxide to healthy elderly adults. Options for the Control of Influenza; 2007 June 17-23; Toronto, Ontario, Canada
86. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007;370(9587):580-9
87. Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008;198(5):642-9
88. Poland GA, Sambhara S. Vaccines against Influenza A (H5N1): evidence of progress J Infect Dis 2008;198(5):629-31
89. Wright PF, Thompson J, Vaughn WK, et al. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977;136(Suppl):S731-41
90. Kunz C, Hofmann H, Bachmayer H, et al. Clinical trials with a new influenza subunit vaccine in adults and children. Dev Biol Stand 1977;39:297-302
91. Nicholson KG, Tyrrell DA, Harrison P, et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 1979;7(2):123-36
92. Stephenson I, Nicholson KG, Gluck R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003;362(9400):1959-66
93. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006;368(9540):991-7
94. Desheva JA, Lu XH, Rekstin AR, et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 2006;24(47-48):6859-66
95. WHO. Tables on the clinical trials of pandemic influenza prototype vaccines. 2007 July 19 [cited 2008 August 21]. Available from: http://www.who.int/vaccine_research/diseases/infiuenza/ flu_trials_tables/en/print.html
96. Karron R. Evaluation of immune responses in clinical trials of live attenuated A/AA ca avian influenza virus vaccines. FDA NIH/WHO Public Workshop: Immune Correlates of Protection Against Influenza A Viruses in Support of Pandemic Vaccine Development. 2007 [cited 2008 August 21]. Available from: http://www.fda.gov/cber/pandemic/panflu121007rk.pdf
97. Powers DC, Fries LF, Murphy BR, et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991;29(3):498-505
98. Ehrlich HJ, Muller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008;358(24):2573-84
99. Available from: www.clinicaltrials.gov
100. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19(13-14):1732-7
101. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008;198(5):635-41
102. Baer J, Goji NA, Nolan C, et al. Rapid cellular immune response to infiuenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Options for the control of influenza; 2007 June 17-23; Toronto, Canada; 2007. p. 39
103. Ramqvist T, Andreasson K, Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 2007;7(7):997-1007
104. Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25(19):3871-8
105. Richardson T. Novavax Announces Favorable Interim Results from Human Clinical Trial for its Pandemic Influenza Vaccine Program. 2007 December 20 [cited 2008 August 21]. Available from: http://www.novavax.com/ download/releases/pandemicinterimresultsPR%20FO.pdf
106. Andrew ME, Coupar BE, Boyle DB, Ada GL. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol 1987;25(1):21-8
107. Gao W, Soloff AC, Lu X, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006;80(4):1959-64
108. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23(8):1029-36
109. Hoelscher MA, Garg S, Bangari DS, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006;367(9509):475-81
110. Bennink JR, Yewdell JW, Smith GL, et al. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 1984;311(5986):578-9
111. Bender BS, Rowe CA, Taylor SF, et al. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996;70(9):6418-24
112. Hubby B, Talarico T, Maughan M, et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007;25(48):8180-9
113. Panicali D, Davis SW, Weinberg RL, Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA 1983;80(17):5364-8
114. Sutter G, Wyatt LS, Foley PL, et al. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to infiuenza virus. Vaccine 1994;12(11):1032-40
115. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003;21 (17-18):1995-2002
116. Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 2004;3(4 Suppl):S89-97
117. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol 2002;2(4):239-50
118. Dorrell L, Williams P, Suttill A, et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/ multi-epitope immunogen (MVA. HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 2007;25 (17):3277-83
119. Frey J, Eberle S, Stahl C, et al. Alternative vaccination against equine botulism (BoNT/C). Equine Vet J 2007;39(6):516-20
120. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24(12):2065-70
121. Hoelscher MA, Jayashankar L, Garg S, et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long lasting protective immune responses in mice. Clin Pharmacol Ther 2007;82(6):665-71
122. Hoelscher MA, Singh N, Garg S, et al. A broadly protective vaccine against globally dispersed Clade 1 and Clade 2 H5N1 influenza viruses. J Infect Dis 2008;197(8):1185-8
123. Alphavax announces results from phase I influenza vaccine clinical trial. 2007 [cited 2008 August 20]. Available from: http://www.alphavax.com/docs/pr/release_43.pdf
124. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259(5102):1745-9
125. Ulmer JB, Fu TM, Deck RR, et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998;72(7):5648-53
126. Webster RG, Fynan EF, Santoro JC, Robinson H. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 1994;12(16):1495-8
127. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995;1(6):583-7
128. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997;15(8):865-8
129. Degano P, Sarphie DF, Bangham CR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 1998;16(4):394-8
130. Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24(21):4475-81
131. Jimenez GS, Planchon R, Wei Q, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007;3(5):157-64
132. Degano P, Schneider J, Hannan CM, et al. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999;18(7-8):623-32
133. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23(46-47):5404-10
134. Epstein SL, Tumpey TM, Misplon JA, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002;8(8):796-801
135. Xie H, Liu T, Chen H, et al. Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid. Vaccine 2007;25(44):7649-55
136. Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007;13(3):426-35
137. Laddy DJ, Yan J, Corbitt N, et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007;25(16):2984-9
138. Vical Expands Clinical Testing of DNA Vaccine Against H5N1 Pandemic Influenza. 2007 [cited 2008 August 21]. Available from: http://www.medicalnewstoday.com/articles/90975.php
139. NIAID DNA Vaccine for H5N1 Avian Influenza Enters Human Trial 2007 [cited 2008 August 21]. Available from: http://www.nih.gov/news/pr/ jan2007/niaid-02.htm
140. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Fields BN, Knipe D M, Howley PM, editors, Fields virology. Philadelphia: Lippincott-Raven Publishers; 1996. p. 1353-95
141. Black RA, Rota PA, Gorodkova N, et al. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993;74(Pt 1):143-6
142. Mozdzanowska K, Feng J, Eid M, et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003;21 (19-20):2616-26
143. Feng J, Zhang M, Mozdzanowska K, et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006;3:102
144. Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999;5(10):1157-63
145. Frace AM, Klimov AI, Rowe T, et al. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999;17(18):2237-44
146. De Filette M, Min Jou W, Birkett A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005;337(1):149-61
147. Fan J, Liang X, Horton MS, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004;22(23-24):2993-3003
148. Huleatt JW, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin, Vaccine 2008;26(2):201-14
149. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002;83(Pt 8):1851-9
150. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004;10(2):71-84
151. Ernst WA, Kim HJ, Tumpey TM, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006;24(24):5158-68
152. Acambis reports positive data from trials of universal influenza A vaccine. 2008 January 03 [cited 2008 August 20]. Available from: http://www.acambis.com/default.asp?id=2039
153. Partidos CD. Antigens onto bare skin: a 'painless' paradigm shift in vaccine delivery. Expert Opin Biol Ther 2003;3(6):895-902
154. Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit Rev Ther Drug Carrier Syst 2001;18(5):503-26
155. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am 2003;23(4):787-813
156. Kenney RT, Yu J, Guebre-Xabier M, et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004;190(4):774-82
157. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351 (22):2286-94
158. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002;20(7-8):1099-105
159. La Montagne JR, Fauci AS. Intradermal influenza vaccination - can less be more? N Engl J Med 2004;351 (22):2330-2
160. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43(9):1135-42
161. Ohrt CK, McKinney WP. Achieving compliance with influenza immunization of medicai house staff and students. A randomized controlled trial. JAMA 1992;267(10):1377-80
162. Ndiaye SM, Hopkins DP, Smith SJ, et al. Methods for conducting systematic reviews of targeted vaccination strategies for the guide to community preventive services. Am J Prev Med 2005;28(5 Suppl):238-47
163. Ndiaye SM, Hopkins DP, Shefer AM, et al. Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review. Am J Prev Med 2005;28(5 Suppl):248-79
164. Available from: http://gamapserver.who.int/mapLibrary/Files/Maps/ Global_H5NlinHumanCUMULATIVE_FIMS_20080619.png
165. Available from: http://gamapserver.who.int/ mapLibrary/Files/Maps/ Global_SubNat_H5N1inAnimalConfirmedCUMULATIVE 20080815.png